Significance of this study
What is already known about this subject? ► Liver tests are among the most frequently ordered tests in medicine and yield abnormal results in more than one in five patients. ► Beyond gathering history, further testing in response to abnormalities remains a matter of debate. ► The majority of clinical guidelines currently recommend repeating the abnormal liver chemistry test as an initial step. ► How clinicians (particularly in primary care) respond to liver test abnormalities and the factors associated with these responses are understudied.
What are the new findings?
► A primary care patient-centered medical home had a period prevalence of 31% for abnormal liver tests. ► Over 11% of patients with abnormal tests did not undergo repeat testing. ► Patients with multiple test abnormalities (of bilirubin, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase) and cholestatic patterns of liver injury underwent repeat testing more often than patients with lone liver test abnormalities or hepatocellular patterns of injury.
How might these results change the focus of research or clinical practice?
► Liver tests are frequently abnormal in primary care; thus, developing systematic, evidence-based strategies for responding to them will be critical for improving quality of care. ► More knowledge is needed to understand how clinicians respond to abnormal liver tests currently, and these responses impact diagnostic and therapeutic processes.
AbSTrACT
Abnormal liver tests are extremely common in clinical practice, present with varying patterns and degrees of elevation, and can signal liver injury from a variety of causes. Responding to these abnormalities requires complex medical decisionmaking and merits investigation in primary care. 
bACkgrOund
Liver tests are among the most frequently ordered tests in medicine and yield abnormal results in more than one in five patients. [1] [2] [3] These tests are inexpensive, reside in easy to order 'panels', and include serum bilirubin, aminotransferases, and alkaline phosphatase. 4 Abnormal liver tests can indicate liver injury from a variety of causes, but may also point to hemolysis, muscle injury, or bone turnover. 5 Test panels present with different combinations and magnitudes of elevation, necessitating complex medical decisions in response to abnormalities. Current approaches to managing liver test abnormalities emphasize the importance of gathering further history, particularly regarding current symptoms (or absence thereof), alcohol use, illicit drug use, medication use (including over-the-counter varieties), and sexual and family histories. 2 6 7 Additionally, body mass index, previous liver chemistry testing results, and patient comorbidities (ie, metabolic syndrome) help to develop context for the abnormalities, providing critical clues to identify the cause.
Beyond the history, further testing remains a matter of debate. Previous studies highlight the varied follow-up strategies clinicians currently employ, as well as evaluate the benefits of sequential versus 'all-at-once' testing. 8 9 While these investigative strategies warrant continued research, the majority of clinical guidelines currently recommend repeating the abnormal liver chemistry test as an initial step. 7 10 11 Such testing, although debated, can provide useful information regarding the trajectory and persistence of the pathologic process (ranging from progression to resolution).
How clinicians (particularly in primary care) respond to liver test abnormalities and the factors associated with these responses are understudied. 8 12 Further, it is not known what patterns of liver test abnormality are most associated with repeat testing in the primary care setting. In this study, we hypothesized that liver test panels with multiple abnormalities would be followed up more often than single abnormalities. We also hypothesized that abnormal liver test panels with cholestatic patterns would be associated with higher proportions of follow-up testing than hepatocellular patterns of abnormality. Therefore, we specifically investigated follow-up of abnormal liver tests in the primary care setting.
MeTHOdS
This retrospective cohort study of patients with abnormal liver tests was performed in an outpatient general internal medicine patient-centered medical home (PCMH) at the Medical University of South Carolina (MUSC). The MUSC Internal Medicine PCMH is a comprehensive internal medicine practice that delivers care to a diverse (49.1% non-white) adult (mean age 58.6 years) population with chronic and complex medical problems (table 1). The clinicians providing care include up to 14 faculty at any given time, along with over 90 medical residents in training.
All adult patients with at least two office visits and one abnormal liver test between July 2007 and June 2016 were included in the analysis. Liver test abnormalities analyzed included those identified in the electronic health record, which included results from the outpatient, inpatient, and emergency room settings within the university health system. Patients entered the cohort on the date of the first liver test abnormality and were followed longitudinally for follow-up testing, until June 30, 2016.
Liver test abnormalities were categorized by the abnormal test(s) in the panel and the degree of abnormality. Patterns and combinations of abnormal liver tests were compared for the endpoint of obtaining repeat liver chemistry testing.
Liver test components included the following tests: total bilirubin (Bili), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP).
Results of the component tests were deemed abnormal when they surpassed the upper limit of the normal reference range for the laboratory at MUSC (Bili>1.2 mg/dL, AST>34 IU/L, ALT>45 IU/L, and ALP>150 IU/L). Patterns of liver test component abnormalities were grouped in two ways. First, abnormal liver panels were categorized based on the number of elevated components, defined as having either single or multiple abnormalities. Next, for those patients with multiple abnormal components, liver tests were categorized into the clinical patterns of hepatocellular injury (AST and ALT), cholestasis (Bili and ALP), and a composite of all other patterns.
The outcome of interest was the proportion of patients without repeat liver studies following the initial abnormality. We excluded follow-up liver tests ordered in the emergency room and inpatient settings, assessed by proxy of a repeat test within 24 hours from the initial abnormality.
The proportions of patients with and without follow-up liver tests were calculated by groups of initial abnormalities and compared using Fisher's exact test. SAS V.9.3 was used for the statistical analysis.
reSulTS
Of the 30,518 unique patients who visited the practice during the study period, 9545 (31.3%) met the inclusion criteria (figure 1). Demographic variables are detailed in table 1. figure 2 ).
Original research
Of the individual liver test components, AST was the test most often abnormal (66% of patients with index liver tests had an abnormal AST value) and featured the highest degree of abnormality (the mean abnormal level was 2.2 times the upper limit of normal (ULN)). ALP was the individual test least often abnormal (15% of included index tests) and possessed the lowest degree of abnormality (the mean abnormal value was 1.5 times the ULN) (table 2). The three most commonly occurring combinations of abnormal liver tests on index testing included the following: AST+ALT (20%), Bili+AST (5.4%), and Bili+AST+ALT (3.1%) ( figure 2) .
Overall, 1119 (11.7%) of the 9545 patients with abnormal liver tests did not have repeat testing performed during the study period. The proportions of patients missing follow-up after an initial abnormality were analyzed by the number of liver test abnormalities on index testing, single versus multiple. Patients with only one abnormal component on their original panel were significantly more likely to not have follow-up (12.6%) than those with multiple abnormal components (10.5%, p=0.003). This difference persisted for tests with mild (1-2 times the ULN) as well as severe (>4 times the ULN) degrees of abnormality on index testing. No significant difference between single and multiple tests was found for moderate (>2-4 times the ULN) degrees of initial abnormality ( figure 3) .
The proportions of patients missing follow-up testing were compared by which test or tests were initially abnormal, and by the degree of initial abnormality (table 3) . A significant difference existed in the percentage of patients missing follow-up for single abnormalities compared with multiple (p<0.001). Among patients with single abnormalities, those with lone AST elevations most often underwent follow-up (missing 10.7%). There was no difference in rates of follow-up by single test abnormalities when the initial studies were moderately (>2-4 times ULN) and severely (>4 times ULN) abnormal. Also, there was no difference in repeat testing for each single abnormal liver test, no matter the degree of initial elevation (table 3) .
For combinations of abnormal liver tests, there was a statistically significant difference in the proportion of patients without follow-up (p<0.001), and the AST-ALT combination of initial abnormality was most often lacking repeat assessment (12.6%). There was no significant difference in rates of follow-up for each combination of abnormality, by degree of initial elevation (table 3) .
diSCuSSiOn
In this study of abnormal liver tests, more than one in three patients in an internal medicine PCMH had an abnormal result, and over 10% of those did not undergo repeat testing. Patients with multiple abnormal liver tests (on index testing) obtained follow-up more often than those with single abnormalities. Proportions of patients without follow-up did not differ by the degree of the initial abnormality, but did differ based on which test(s) exceeded their reference range.
We were surprised to find that more than 1 in 10 (11.7%) patients with an initial abnormal liver test did not have a documented repeat test during the study period. Multiple potential reasons for this finding exist. First, it is possible that some of these patients underwent directed testing for liver disease (ie, viral hepatitis serology, imaging, and others) in lieu of repeat chemistries. 6 13 Further, some of these patients may have undergone additional assessment with other providers in other healthcare systems, results of which may not have been available in this administrative data investigation. We think this latter possibility is unlikely since the patients included in this study were included only after visiting the PCMH on two occasions, and the PCMH itself does not serve as a referral destination. It should also be emphasized that the outcome of interest in this study (repeat testing) reflects physician-ordering practices and the ability of the patient to obtain repeat testing. Indeed, follow-up care relies on effective communication and patient access, and any barriers to these confronted by patients would likely result in lower proportions of those obtaining repeat testing. While an imperfect marker for assessing follow-up, a second measurement (particularly in the absence of historical results) provides valuable clinical information and opportunities to investigate how clinicians and patients respond to abnormal liver tests in the primary care setting.
Original research
Although it was not surprising to find that a lower proportion of patients with single liver test abnormalities had repeat testing compared with patients with multiple abnormal tests, it was informative to examine follow-up as a function of initial liver test abnormality. Notably, a higher proportion of patients with initial AST abnormalities had repeat testing than those with initial ALT abnormalities. This is surprising given AST's known lack of specificity (ie, non-hepatic causes of elevation including being derived from red blood cells, skeletal muscle, and kidney), and ALT's role as the most important test indicating acute and chronic hepatic injury. 4 5 Such a finding may be indicative of clinicians pursuing liver-focused testing in the setting of ALT elevation and bypassing a repeat of liver chemistries. 6 13 We tend to doubt this possibility given usual clinical practice in that liver tests would likely have been obtained at the same time as follow-up liver-focused testing.
At least 13% of patients with isolated elevations in Bili lacked repeat liver chemistry testing, with an even greater proportion (22%) not receiving testing when the bilirubin exceeded 4.8 mg/dL (4 times the ULN). On one hand, this absence of repeat testing is surprising given the association of bilirubin elevation with mortality in liver disease, as well as Hy's law in the setting of drug-induced liver injury.
14 On the other hand, Gilbert's disease, an inherited metabolic disorder with impaired bilirubin conjugation, represents the most common cause of isolated bilirubin elevation. 15 A benign condition, such a diagnosis would not merit repeat assessment. A chart review of the nine patients with marked (4 times above the ULN) lone bilirubin elevation identified a diagnosis of sickle cell anemia in eight of the patients and intrahepatic cholestasis of pregnancy in the other. The latter condition resolves with delivery and may not require additional assessment, and sickle cell disease results in hemolysis with elevated bilirubin levels exacerbated by vaso-occlusive episodes, which may ebb and flow with the onset and resolution of crises. These data suggest that clinicians who encounter certain abnormal liver tests are likely to integrate the abnormal liver tests into their clinical decision-making processes and intentionally choose not to repeat liver tests.
When multiple liver tests were abnormal, a higher proportion of patients with the hepatocellular patterns of elevation (AST and ALT) went without follow-up compared with other combinations and patterns. We speculate that this finding presents an important opportunity to improve patient care due to the volume of patients with the abnormality (1909) and the relation to potentially treatable, hepatocellular disorders, including alcohol-related liver disease, non-alcoholic fatty liver disease, and viral hepatitis (in particular, hepatitis C virus (HCV)). While it would be reasonable to follow up such abnormalities with directed testing (ie, history of alcohol use, HCV serology, imaging), providers need to ensure that some continued assessment of the abnormal aminotransferase elevation occurs in order to arrive at a timely, accurate diagnosis and initiate behavioral and/or medical therapy. Further study into different diagnostic pathways merits investigation.
Timely and appropriate response to abnormal liver tests may play a critical role in the iterative diagnostic process of liver disease, allowing for earlier treatment and potential avoidance of downstream complications including cirrhosis and hepatocellular carcinoma. Diagnostic error is the 'failure to establish an accurate and timely explanation of the patient's health problem(s) or communicate that explanation to the patient'. 16 The Institute of Medicine has called for improvements in the diagnostic process, labeling this cause as a 'moral, professional, and public health imperative'. 16 Reducing diagnostic error in liver disease will rely on the successful integration of healthcare teamwork (primary care and hepatology), effective use of information technology, and evidence-based refinements to the diagnostic process. Here, we have identified repeat liver test testing as a potential opportunity to reduce diagnostic error. Of note, the outcome here combines elements of provider recognition and patient communication. We speculate that substantial further work will need to be done to link diagnostic strategies to liver disease-related outcomes.
We recognize the limitations of this study. First, we realize that repeat liver tests are not necessarily the only means of assessing intrinsic liver disease and may not directly lead to diagnostic conclusions. However, given the consistency with which repeat assessment appears in published guidelines for managing abnormal liver tests, this outcome serves as a first step in assessing current responses to abnormal liver panels. Additionally, we recognize that this study did not link abnormal liver tests to diagnostic conclusions or outcomes. Future investigation is needed in this area, particularly in the primary care setting. We also appreciate that these data originate from a single center and may not be generalizable to other populations. However, given that the sample was derived from an outpatient general medicine clinic, we suspect it may be more generalizable than the one obtained from a specialty clinic or inpatient setting. Further, we were unable to determine whether the initial liver test abnormality was, in fact, the patient's first documented evaluation, as the laboratory data we examined were derived from our electronic medical record and does not reliably incorporate data from all external healthcare providers and institutions. This limits the ability to identify abnormal studies outside of the institution (either prior to cohort inclusion or in follow-up). Prior abnormalities would likely influence decisions for future testing, leading to fewer tests based on the chronicity of abnormality, and potentially impacting the interpretation of the results. However, we suspect this occurred infrequently given the study design, which was to include only patients with two or more visits, which would enrich the population with patients who had primary care in our clinic and reduce the number of patients with outside follow-up.
COnCluSiOn
In summary, we found that abnormal liver tests were pervasive in a primary care clinic and that a substantial number of these did not undergo repeat assessment. Higher proportions of patients with multiple liver test abnormalities had repeat testing compared with those with individual abnormalities. The data raise the possibility that there are substantial future opportunities for study of liver tests in the primary care setting, with opportunities to improve care delivery.
